Partners in AML: Flt3 and c-Cbl

Research output: Contribution to journalReview article


In this Issue of Blood, Sargin and colleagues identify a mutation in the negative regulator c-Cbl in human acute myelold leukemia (AML) that mirrors the effects seen with oncogenic Flt3 receptors. Thus, an alternative mechanism for the inappropriate activation of receptor tyrosine kinases (RTKs) in tumors occurs through inactivation of a negative regulator.
Original languageEnglish
Pages (from-to)793-794
Issue number3
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Partners in AML: Flt3 and c-Cbl'. Together they form a unique fingerprint.

Cite this